

## CASE DEFINITION FOR COVID-19 STUDY:

Report any new patient less than 18 years of age (up to the 18<sup>th</sup> birthday) who meets one of the following three case definitions:

- (1) HOSPITALIZED with acute COVID-19 (i.e., microbiologically confirmed SARS-CoV-2)
- (2) HOSPITALIZED with paediatric inflammatory multisystem syndrome (PIMS)/Kawasaki disease temporally associated with COVID-19, defined as:

- Persistent fever (>38 degrees Celsius for 3 or more days) and elevated inflammatory markers (C-reactive protein [CRP], erythrocyte sedimentation rate [ESR], or ferritin)

AND one or both of the following:

- Features of Kawasaki disease (complete or incomplete)
- Toxic shock syndrome (typical or atypical)

AND

- No alternative etiology to explain the clinical presentation

**IMPORTANT NOTE:** *Patients should be reported regardless of SARS-CoV-2 status*

- (3) NON-HOSPITALIZED with acute COVID-19 (i.e., microbiologically confirmed SARS-CoV-2) AND at least one of the following chronic comorbid conditions:

< 12 months of age	Asthma
Obesity	Chronic lung disease
Congenital heart disease	Chronic renal disease
Immunocompromising medications (high-dose steroids,* chemotherapy, biologics, immunomodulators)	Solid tumor or hematologic malignancy
Solid organ transplant	Bone marrow transplant
Primary or secondary immunodeficiency	Chronic neurologic or neurodevelopmental condition
Sickle cell disease or other chronic hematologic condition	Diabetes
Tracheostomy	Chronic rheumatologic or autoimmune disease
Inflammatory bowel disease or other chronic gastrointestinal or liver disease	Genetic/metabolic disease

\* Equivalent to at least 2 mg/kg or 20 mg/day of prednisone for at least two weeks